• Leukemias, lymphomas, and other hematologic cancers

Campath Generic Name & Formulations

General Description

Alemtuzumab 30mg/mL; soln for IV infusion after dilution; preservative-free.

Pharmacological Class

Monoclonal antibody, CD52 (recombinant, humanized).

How Supplied

Single-use vial—1, 3


Campath Indications


B-cell chronic lymphocytic leukemia (B-CLL).

Campath Dosage and Administration


Premedicate with antihistamine and acetaminophen before 1st dose, and at dose escalations. Give by IV infusion over 2hrs. Initially 3mg daily until infusion-related reactions are ≤ grade 2, then increase to 10mg daily until infusion-related reactions are ≤ grade 2, then to maintenance 30mg/day three times per week (on alternate days); duration of therapy (including escalation): 12 weeks. Do not exceed max single dose 30mg/dose or 90mg/week. Give PCP and herpes viral prophylaxis during treatment and for at least 2 months after completion or until CD4+ count ≥200cells/µL, whichever occurs later. Dose adjustments for neutropenia and thrombocytopenia: see full labeling. Retitrate if therapy interrupted for ≥7 days.


Not established.

Campath Contraindications

Not Applicable

Campath Boxed Warnings

Boxed Warning

Cytopenias. Infusion-related reactions. Infections.

Campath Warnings/Precautions


Withhold dose for severe cytopenias (except lymphopenia); discontinue if autoimmune or recurrent/persistent severe cytopenias (except lymphopenia) develop. Monitor for infusion-related reactions; withhold dose if grade 3 or 4. Monitor for CMV infection during and for at least 2 months after completion. Withhold dose for serious infections and during antiviral treatment for CMV infection or confirmed CMV viremia. Monitor for Epstein-Barr virus (EBV) infections; withhold if reactivation or severe infection. Obtain CBCs, platelet counts weekly, assess CD4+ counts after treatment until recovery to ≥200cells/µL. Pregnancy: exclude status prior to initiation. Advise females of reproductive potential to use effective contraception during and for ≥3 months after the last dose. Nursing mothers: not recommended (during and for ≥3 months after the last dose).

Campath Pharmacokinetics

See Literature

Campath Interactions


Avoid live virus vaccines (after recent alemtuzumab therapy) to patients or infants born to patients receiving treatment. May interfere with tests using antibodies. Irradiate any blood products given (GVHD may occur).

Campath Adverse Reactions

Adverse Reactions

Infusion-related reactions, cytopenias (eg, neutropenia, lymphopenia, thrombocytopenia, anemia), infections (eg, CMV, EBV), nausea, emesis, diarrhea, insomnia, anxiety.

Campath Clinical Trials

See Literature

Campath Note

Not Applicable

Campath Patient Counseling

See Literature